lenalidomide has been researched along with Invasiveness, Neoplasm in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Hagiwara, S; Hanamura, I; Handa, H; Iida, S; Ikeda, T; Imaizumi, Y; Itagaki, M; Kawamura, K; Kondo, T; Kuroda, J; Murakami, J; Nagai, H; Nakamura, Y; Nakao, S; Nakazawa, H; Okura, M; Ozaki, S; Sunami, K; Takahashi, T; Takamatsu, H; Takeuchi, M; Watakabe-Inamoto, K; Yamashita, T | 1 |
| Chen, Y; Fang, Y; Fei, XC; Janin, A; Jiang, XF; Leboeuf, C; Li, B; Song, Q; Sun, YF; Wang, CF; Wang, L; Xu, PP; Yan, ZX; Zhao, WL; Zhao, Y | 1 |
| Barrio, S; Braggio, E; Collado, L; Folgueira, MD; Hernandez-Lain, A; Linares, M; Martinez-Lopez, J; Ramos, A; Rapado, I; Ruiz, J; Ruiz-Heredia, Y; Sanchez-Vega, B; Stewart, K; Toldos, O | 1 |
| Guo, HM; Liu, XJ; Luo, JM; Nie, ZY; Sun, L; Yang, L | 1 |
| Kato, T; Miyao, K; Niimi, K; Ono, Y; Sakai, T; Sakemura, R; Sawa, M; Tsushita, N | 1 |
| Abdelrahim, M; Bilen, MA; Erguvan-Dogan, B; Falchook, GS; Fu, S; Hong, DS; Kurzrock, R; Naing, A; Ng, CS; Tsimberidou, AM; Wheler, JJ | 1 |
| Afanasyev, B; Alexeeva, J; Arcaini, L; Belada, D; Biyukov, T; Bravo, MC; Giza, A; Jurczak, W; Kaplanov, K; Kuliczkowski, K; Kuzmin, A; Lamy, T; Marks, R; Mayer, J; Milpied, N; Morschhauser, F; Patturajan, M; Radford, J; Rule, S; Stelitano, C; Thyss, A; Trněný, M; Trümper, L; Voloshin, S; Walewski, J | 1 |
| Bartlett, JB; Dalgleish, AG; Galustian, C; Henry, JY; Liu, WM; Meyer, B | 1 |
2 trial(s) available for lenalidomide and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Phase I trial of valproic acid and lenalidomide in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Thalidomide; Treatment Outcome; Valproic Acid | 2015 |
Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Prospective Studies; Survival Analysis; Thalidomide; Treatment Outcome | 2016 |
6 other study(ies) available for lenalidomide and Invasiveness, Neoplasm
| Article | Year |
|---|---|
A nationwide survey on central nervous system multiple myeloma in Japan: analysis of prognostic and treatment factors that impact survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Central Nervous System; Combined Modality Therapy; Female; Humans; Immunologic Factors; Injections, Spinal; Japan; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Invasiveness; Prognosis; Radiotherapy; Research Design; Retrospective Studies; Surveys and Questionnaires; Survival Analysis | 2021 |
JAM-A overexpression is related to disease progression in diffuse large B-cell lymphoma and downregulated by lenalidomide.
Topics: Animals; Cell Adhesion Molecules; Cell Line, Tumor; Disease Progression; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Lymphatic Metastasis; Lymphoma, Large B-Cell, Diffuse; Male; Mice; Neoplasm Invasiveness; Nodal Protein; Prognosis; Receptors, Cell Surface; Signal Transduction; Transforming Growth Factor beta; Up-Regulation; Xenograft Model Antitumor Assays; Zebrafish | 2017 |
Concurrent progressive multifocal leukoencephalopathy and central nervous system infiltration by multiple myeloma: A case report.
Topics: Aged; Brain; Dexamethasone; Female; Humans; JC Virus; Lenalidomide; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Multiple Myeloma; Neoplasm Invasiveness | 2019 |
Microvesicles shed from bortezomib-treated or lenalidomide-treated human myeloma cells inhibit angiogenesis in vitro.
Topics: Bortezomib; Cell Line, Tumor; Cell Movement; Cell-Derived Microparticles; Coculture Techniques; Down-Regulation; Fibroblast Growth Factor 2; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; In Vitro Techniques; Interleukin-6; Lenalidomide; Multiple Myeloma; Neoplasm Invasiveness; Neovascularization, Pathologic; Thalidomide; Vascular Endothelial Growth Factor A | 2018 |
Testicular invading refractory multiple myeloma during bortezomib treatment successfully treated with lenalidomide: a case report.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Genital Neoplasms, Male; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Invasiveness; Orchiectomy; Proteasome Inhibitors; Pyrazines; Secondary Prevention; Spermatic Cord; Stem Cell Transplantation; Testicular Neoplasms; Thalidomide; Vincristine | 2014 |
Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs).
Topics: Animals; Antineoplastic Agents; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Immunoblotting; Immunohistochemistry; Immunologic Factors; Lenalidomide; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasm Invasiveness; Neoplasm Metastasis; Signal Transduction; Thalidomide; Tumor Cells, Cultured | 2009 |